PT954299E - Analogos de tiroxina sem actividade hormonal significativa, para o tratamento de tumores malignos - Google Patents

Analogos de tiroxina sem actividade hormonal significativa, para o tratamento de tumores malignos

Info

Publication number
PT954299E
PT954299E PT97927813T PT97927813T PT954299E PT 954299 E PT954299 E PT 954299E PT 97927813 T PT97927813 T PT 97927813T PT 97927813 T PT97927813 T PT 97927813T PT 954299 E PT954299 E PT 954299E
Authority
PT
Portugal
Prior art keywords
malignant tumors
treatment
thyroxine
significant hormonal
analogues
Prior art date
Application number
PT97927813T
Other languages
English (en)
Inventor
Ernest Kun
Mendeleyev Jerome
Original Assignee
Octamer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/655,267 external-priority patent/US5736576A/en
Application filed by Octamer Inc filed Critical Octamer Inc
Publication of PT954299E publication Critical patent/PT954299E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT97927813T 1996-06-04 1997-05-30 Analogos de tiroxina sem actividade hormonal significativa, para o tratamento de tumores malignos PT954299E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/655,267 US5736576A (en) 1996-06-04 1996-06-04 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US08/833,272 US6017958A (en) 1996-06-04 1997-04-03 Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity

Publications (1)

Publication Number Publication Date
PT954299E true PT954299E (pt) 2005-11-30

Family

ID=27096941

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97927813T PT954299E (pt) 1996-06-04 1997-05-30 Analogos de tiroxina sem actividade hormonal significativa, para o tratamento de tumores malignos

Country Status (15)

Country Link
US (1) US6017958A (pt)
EP (1) EP0954299B1 (pt)
JP (1) JP4188416B2 (pt)
CN (1) CN1154486C (pt)
AT (1) ATE300292T1 (pt)
AU (1) AU730261B2 (pt)
BR (1) BR9710686A (pt)
CA (1) CA2257235C (pt)
DE (1) DE69733834T2 (pt)
DK (1) DK0954299T3 (pt)
ES (1) ES2246514T3 (pt)
IL (1) IL127384A0 (pt)
NZ (1) NZ333356A (pt)
PT (1) PT954299E (pt)
WO (1) WO1997046228A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity
JP2002507567A (ja) * 1998-03-25 2002-03-12 ラージ スケール バイオロジー コーポレイション 血管形成を阻害するための安息香酸誘導体
US6433012B1 (en) * 1998-03-25 2002-08-13 Large Scale Biology Corp. Method for inhibiting inflammatory disease
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US6677473B1 (en) 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
US7504435B2 (en) 2001-01-31 2009-03-17 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method for stimulating weight loss and/or for lowering triglycerides in patients
US20050159490A1 (en) * 2001-01-31 2005-07-21 Eugene Morkin Method to treat chronic heart failure and/or elevated cholesterol levels
AUPR500201A0 (en) 2001-05-14 2001-06-07 Commonwealth Scientific And Industrial Research Organisation Recovery of minerals by flotation
IL165323A0 (en) 2002-06-06 2006-01-15 Canbas Co Ltd Compounds that abrogate dna-damage-induced cell c ycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
US7358046B2 (en) * 2003-08-08 2008-04-15 Canbas Co., Ltd. Sensitivity test to predict efficacy of anti-cancer therapies
US20050249667A1 (en) * 2004-03-24 2005-11-10 Tuszynski Jack A Process for treating a biological organism
JP5177429B2 (ja) * 2005-07-18 2013-04-03 バイパー サイエンシズ，インコーポレイティド 癌の治療
EP1953148B1 (en) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
US20100279327A1 (en) * 2006-06-12 2010-11-04 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20080262062A1 (en) * 2006-11-20 2008-10-23 Bipar Sciences, Inc. Method of treating diseases with parp inhibitors
US20070292883A1 (en) * 2006-06-12 2007-12-20 Ossovskaya Valeria S Method of treating diseases with PARP inhibitors
AU2007292387A1 (en) * 2006-09-05 2008-03-13 Bipar Sciences, Inc. Treatment of cancer
CA2662335A1 (en) * 2006-09-05 2008-03-13 Valeria Ossovskaya Methods for designing parp inhibitors and uses thereof
US7538252B2 (en) * 2006-09-05 2009-05-26 Bipar Sciences, Inc. Drug design for tubulin inhibitors, compositions, and methods of treatment thereof
EP2061479A4 (en) * 2006-09-05 2010-08-04 Bipar Sciences Inc FETTIC ACID SYNTHESIS INHIBITED BY PARP HEMMER AND TREATMENT PROCEDURES THEREWITH
US8133859B2 (en) 2006-09-27 2012-03-13 The United States Of America As Represented By The Department Of Health And Human Services SCGB3A2 as a growth factor and anti-apoptotic agent
CN101903025A (zh) * 2007-10-19 2010-12-01 彼帕科学公司 利用苯并吡喃酮-型parp抑制剂治疗癌症的方法和组合物
MX2010005221A (es) * 2007-11-12 2010-09-28 Bipar Sciences Inc Tratamiento de cancer de utero y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes antitumorales.
CA2705537A1 (en) * 2007-11-12 2009-05-22 Bipar Sciences, Inc. Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2009073869A1 (en) * 2007-12-07 2009-06-11 Bipar Sciences, Inc. Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
CN101999002A (zh) * 2008-02-04 2011-03-30 彼帕科学公司 诊断和治疗parp-介导的疾病的方法
CN102858156B (zh) 2010-04-28 2015-09-23 奥斯娜特·阿舒尔-费边 用于提供治疗的方法、组合物和试剂盒
HUE035222T2 (hu) * 2012-08-20 2018-05-02 Merck Patent Gmbh Levotiroxint tartalmazó szilárd gyógyszerészeti készítmények
US10874641B2 (en) 2016-07-28 2020-12-29 Mitobridge, Inc. Methods of treating acute kidney injury
JP2020500214A (ja) 2016-11-02 2020-01-09 イミュノジェン・インコーポレーテッド 抗体薬物複合体とｐａｒｐ阻害剤との併用治療
EP3655418A4 (en) 2017-06-22 2021-05-19 Triact Therapeutics, Inc. METHOD OF TREATMENT OF GLIOBLASTOMA
EP3687501A4 (en) 2017-09-29 2021-06-23 Triact Therapeutics, Inc. INIPARIB FORMS AND USES THEREOF
US11874276B2 (en) 2018-04-05 2024-01-16 Dana-Farber Cancer Institute, Inc. STING levels as a biomarker for cancer immunotherapy
US20220305048A1 (en) 2019-08-26 2022-09-29 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB642159A (en) * 1947-10-23 1950-08-30 Glaxo Lab Ltd Improvements in or relating to the preparation of diphenyl ethers
GB643089A (en) * 1947-10-23 1950-09-15 Glaxo Lab Ltd Improvements in or relating to the preparation of 2:6-dihalogeno diphenyl ethers
US4724234A (en) * 1982-09-17 1988-02-09 Therapeutical Systems Corp. Method for producing oncolysis
US4816255A (en) * 1985-07-31 1989-03-28 Ghent William R Treatment of iodine deficiency breast syndrome
WO1993002444A1 (en) * 1991-07-24 1993-02-04 Vladislav Vladimirovich Volkov Tensioning device for keyboard stringed musical instrument
AU4090093A (en) * 1992-05-29 1993-12-30 Yamanouchi Pharmaceutical Co., Ltd. Medicine containing benzoic acid derivative and novel benzoic acid derivative
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
US5883294A (en) * 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
US5922775A (en) * 1997-10-23 1999-07-13 Octamer, Inc. Method of treating malignant tumors with ketone thyroxine analogues having no significant hormonal activity

Also Published As

Publication number Publication date
WO1997046228A1 (en) 1997-12-11
ES2246514T3 (es) 2006-02-16
US6017958A (en) 2000-01-25
EP0954299B1 (en) 2005-07-27
ATE300292T1 (de) 2005-08-15
DE69733834D1 (de) 2005-09-01
DK0954299T3 (da) 2005-10-31
BR9710686A (pt) 2000-01-11
AU3218297A (en) 1998-01-05
CA2257235C (en) 2007-01-30
DE69733834T2 (de) 2006-06-01
EP0954299A4 (en) 2000-09-06
JP2001501590A (ja) 2001-02-06
AU730261B2 (en) 2001-03-01
IL127384A0 (en) 1999-10-28
CN1154486C (zh) 2004-06-23
CA2257235A1 (en) 1997-12-11
JP4188416B2 (ja) 2008-11-26
NZ333356A (en) 2000-06-23
CN1226826A (zh) 1999-08-25
EP0954299A1 (en) 1999-11-10

Similar Documents

Publication Publication Date Title
PT954299E (pt) Analogos de tiroxina sem actividade hormonal significativa, para o tratamento de tumores malignos
AU1195499A (en) Thyroxine analogues having no significant hormonal activity to treat malignant tumors
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ES2137554T3 (es) 2-(2-amino-3-metoxifenil)-4-oxo-4h-(1)benzopirano para el tratamiento de desordenes proliferantes.
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
ATE331534T1 (de) Anwendung von zielgerichtetem radium 223 für palliative und therapeutische behandlung von knochenkrebs
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69737066D1 (de) Verwendung von activem vitamin d analoga zur behandlung von prostataerkrangkungen
ATE501722T1 (de) Therapeutische behandlung androgenrezeptorbedingter leiden
CA2301032A1 (en) A method of preventing or treating estrogen-dependent diseases and disorders
BR9805544A (pt) Uso de um composto.
ATE249233T1 (de) Verwendung von gonadotropin releasing hormon analogen oder änlichen verbindungen zur herstellung von pharmazeutischen zubereitungen als zusatz für invasiver behandlung von karzinomen
NO994330D0 (no) Metode for behandling av en tumor
SE9601396D0 (sv) New therapeutic treatment 2
PA8453601A1 (es) Inhibidores de la farnesil transferasa combinados con inhibidores de la hmg coa reductasa para tratamiento del cancer
BR9808263A (pt) Processos para tratar câncer em um humano em necessidade de tratamento e para manufaturar um medicamento para inibir o crescimento em um humano de um tumor sólido, e, uso de um composto.
PT100111A (pt) Composicao para o tratamento de um mamifero sofrendo de doenca proliferativa dapele, benigna ou maligna, compreendendo um analogo de somatostatina
DE69732851D1 (de) Verwendung von dextrinsulfat zur behandlung von sehr vasculären tumoren
BR9007080A (pt) Aplicacao de derivados de 1,2-benzopirona para o tratamento de tumores malignos no homem
ECSP982800A (es) Metodos para el tratamiento de enfermedades proliferativas
MX9701832A (es) Nuevos profarmacos para la terapia de tumores y enfermedades inflamatorias.